BridgeBio Pharma (BBIO) Debt to Equity: 2019-2025
Historic Debt to Equity for BridgeBio Pharma (BBIO) over the last 6 years, with Sep 2025 value amounting to -$0.38.
- BridgeBio Pharma's Debt to Equity fell 7.03% to -$0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.38, marking a year-over-year decrease of 7.03%. This contributed to the annual value of -$0.50 for FY2024, which is 52.69% down from last year.
- Latest data reveals that BridgeBio Pharma reported Debt to Equity of -$0.38 as of Q3 2025, which was up 23.91% from -$0.50 recorded in Q4 2024.
- In the past 5 years, BridgeBio Pharma's Debt to Equity ranged from a high of -$0.14 in Q3 2021 and a low of -$0.50 during Q4 2024.
- Moreover, its 3-year median value for Debt to Equity was -$0.37 (2023), whereas its average is -$0.38.
- Per our database at Business Quant, BridgeBio Pharma's Debt to Equity tumbled by 217.81% in 2021 and then soared by 30.23% in 2022.
- BridgeBio Pharma's Debt to Equity (Quarterly) stood at -$0.50 in 2021, then surged by 30.23% to -$0.35 in 2022, then grew by 4.90% to -$0.33 in 2023, then tumbled by 52.69% to -$0.50 in 2024, then dropped by 7.03% to -$0.38 in 2025.
- Its Debt to Equity stands at -$0.38 for Q3 2025, versus -$0.50 for Q4 2024 and -$0.36 for Q3 2024.